title: Effect of olsalazine on sodium-dependent bile acid transport in rat ileum.
abstract: Olsalazine (OLZ), a relatively new form of 5-aminosalicylic acid (5-ASA), is being used for the treatment of colitis. A major side effect of olsalazine is diarrhea, reported in 12-25% of patients. One suggested mechanism for this side effect is enhanced ileal water and electrolyte secretion. We propose that OLZ may also inhibit ileal bile acid (BA) transport, resulting in choleretic diarrhea. This would result in excess BAs reaching the colon, with consequent BA-induced secretory diarrhea. Therefore, we studied the effect of OLZ on rat ileal absorption of taurocholate. BA uptake was determined in rat ileal segments, everted sacs, brush border membrane vesicles (BBMV), and Xenopus laevis oocytes. Segments and everted sacs were treated with 5 mM OLZ for 30 min prior to and throughout 10-min taurocholate (Tc) uptake. Terminal ileal BBMV were used to study the effect of OLZ on sodium-dependent bile acid uptake independent of cellular metabolism. Direct effects on the bile acid carrier were examined using Xenopus laevis oocytes expressing the cloned apical rat ileal BA transporter. In ileal segments 5 mM OLZ inhibited 10-min Tc uptake by 69.4 +/- 8.8% (P < 0.01) (N = 10 animals). Increasing concentrations of OLZ resulted in a dose-dependent inhibition of Tc uptake. Ten-minute Tc uptake with 0.5, 1.0, 2.0, 2.5, and 5 mM OLZ was inhibited by 13.5, 39.6, 49.7, and 70.5%, respectively. In BBMV, OLZ inhibited 45-sec Tc uptake in a dose-dependent manner but did not effect Na-dependent L-alanine uptake.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pediatrics, North Shore University Hospital-Cornell University Medical College, Manhasset, NY, USA.
authors.forename: A
authors.initials: A
authors.lastname: Chawla
authors.forename: P I
authors.initials: PI
authors.lastname: Karl
authors.forename: R N
authors.initials: RN
authors.lastname: Reich
authors.forename: G
authors.initials: G
authors.lastname: Narasimhan
authors.forename: G A
authors.initials: GA
authors.lastname: Michaud
authors.forename: S E
authors.initials: SE
authors.lastname: Fisher
authors.forename: B L
authors.initials: BL
authors.lastname: Schneider
mesh_terms: D000636:Aminosalicylic Acids / Q000009:adverse effects / Q000494:pharmacology*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology*; D001647:Bile Acids and Salts / Q000378:metabolism*; D001692:Biological Transport / Q000187:drug effects; D002352:Carrier Proteins / Q000187:drug effects / Q000378:metabolism; D003967:Diarrhea / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D007082:Ileum / Q000187:drug effects* / Q000378:metabolism; D007408:Intestinal Absorption / Q000187:drug effects*; D008297:Male; D008871:Microvilli / Q000378:metabolism; D009865:Oocytes / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012964:Sodium / Q000378:metabolism*; D013656:Taurocholic Acid / Q000493:pharmacokinetics; D014982:Xenopus laevis
chemical_list: D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001647:Bile Acids and Salts; D002352:Carrier Proteins; D013656:Taurocholic Acid; D012964:Sodium; C032587:olsalazine